BMY intended to expand manufacturing capacity in Europe and Japan, with Reuters reporting the decision.
1 report, 1 independent
Updated Aug 27
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
BMY intended to expand manufacturing capacity in Europe and Japan, with Reuters reporting the decision.
Who's involved
What this event is mainly aboutKeep exploring
Part of
The generic drug market is seeing significant growth, driven by Indian firms and regional markets, with major players like Aurobindo, J&J, and GSK involved.Also in this story
- Indian drug makers are targeting the North American market.
- Major pharmaceutical companies, including Johnson & Johnson, GlaxoSmithKline, and Viatris, are key players in the Paracetamol Market.
- Arosi's successful launch and aggressive pricing from generic competition are impacting the pharmaceutical market.
The entities involved
-
Johnson & Johnson
U.S multinational medical devices, pharmaceutical and consumer packaged goods manufacturer
-
Europe
terrestrial continent located in north-western Eurasia